% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brendel:154698,
      author       = {Brendel, Matthias and Barthel, Henryk and van Eimeren,
                      Thilo and Marek, Ken and Song, Mengmeng and Palleis, Carla
                      and Gehmeyr, Mona and Beyer, Leonie and Fietzek, Urban and
                      Respondek, Gesine and Sauerbeck, Julia and Nitschmann,
                      Alexander and Zach, Christian and Hammes, Jochen and Barbe,
                      Michael T and Onur, Oezguer and Jessen, Frank and Saur,
                      Dorothee and Schroeter, Matthias L and Rumpf, Jost-Julian
                      and Rullmann, Michael and Schildan, Andreas and Patt,
                      Marianne and Neumaier, Bernd and Barret, Olivier and
                      Madonia, Jennifer and Russell, David S and Stephens, Andrew
                      and Roeber, Sigrun and Herms, Jochen and Bötzel, Kai and
                      Classen, Joseph and Bartenstein, Peter and Villemagne,
                      Victor and Levin, Johannes and Höglinger, Günter and
                      Drzezga, Alexander and Seibyl, John and Sabri, Osama},
      title        = {{A}ssessment of 18{F}-{PI}-2620 as a {B}iomarker in
                      {P}rogressive {S}upranuclear {P}alsy.´ment},
      journal      = {JAMA neurology},
      volume       = {77},
      number       = {11},
      issn         = {2168-6149},
      address      = {Chicago, Ill.},
      publisher    = {American Medical Association},
      reportid     = {DZNE-2021-00307},
      pages        = {1408 -},
      year         = {2020},
      abstract     = {Progressive supranuclear palsy (PSP) is a 4-repeat
                      tauopathy. Region-specific tau aggregates establish the
                      neuropathologic diagnosis of definite PSP post mortem.
                      Future interventional trials against tau in PSP would
                      strongly benefit from biomarkers that support diagnosis.To
                      investigate the potential of the novel tau radiotracer
                      18F-PI-2620 as a biomarker in patients with clinically
                      diagnosed PSP.In this cross-sectional study, participants
                      underwent dynamic 18F-PI-2620 positron emission tomography
                      (PET) from 0 to 60 minutes after injection at 5 different
                      centers (3 in Germany, 1 in the US, and 1 in Australia).
                      Patients with PSP (including those with Richardson syndrome
                      [RS]) according to Movement Disorder Society PSP criteria
                      were examined together with healthy controls and controls
                      with disease. Four additionally referred individuals with
                      PSP-RS and 2 with PSP-non-RS were excluded from final data
                      analysis owing to incomplete dynamic PET scans. Data were
                      collected from December 2016 to October 2019 and were
                      analyzed from December 2018 to December 2019.Postmortem
                      autoradiography was performed in independent PSP-RS and
                      healthy control samples. By in vivo PET imaging, 18F-PI-2620
                      distribution volume ratios were obtained in globus pallidus
                      internus and externus, putamen, subthalamic nucleus,
                      substantia nigra, dorsal midbrain, dentate nucleus,
                      dorsolateral, and medial prefrontal cortex. PET data were
                      compared between patients with PSP and control groups and
                      were corrected for center, age, and sex.Of 60 patients with
                      PSP, 40 $(66.7\%)$ had RS (22 men $[55.0\%];$ mean [SD] age,
                      71 [6] years; mean [SD] PSP rating scale score, 38 [15];
                      score range, 13-71) and 20 $(33.3\%)$ had PSP-non-RS (11 men
                      $[55.0\%];$ mean [SD] age, 71 [9] years; mean [SD] PSP
                      rating scale score, 24 [11]; score range, 11-41). Ten
                      healthy controls (2 men; mean [SD] age, 67 [7] years) and 20
                      controls with disease (of 10 $[50.0\%]$ with Parkinson
                      disease and multiple system atrophy, 7 were men; mean [SD]
                      age, 61 [8] years; of 10 $[50.0\%]$ with Alzheimer disease,
                      5 were men; mean [SD] age, 69 [10] years). Postmortem
                      autoradiography showed blockable 18F-PI-2620 binding in
                      patients with PSP and no binding in healthy controls. The in
                      vivo findings from the first large-scale observational study
                      in PSP with 18F-PI-2620 indicated significant elevation of
                      tracer binding in PSP target regions with strongest
                      differences in PSP vs control groups in the globus pallidus
                      internus (mean [SD] distribution volume ratios: PSP-RS, 1.21
                      [0.10]; PSP-non-RS, 1.12 [0.11]; healthy controls, 1.00
                      [0.08]; Parkinson disease/multiple system atrophy, 1.03
                      [0.05]; Alzheimer disease, 1.08 [0.06]). Sensitivity and
                      specificity for detection of PSP-RS vs any control group
                      were $85\%$ and $77\%,$ respectively, when using
                      classification by at least 1 positive target region.This
                      multicenter evaluation indicates a value of 18F-PI-2620 to
                      differentiate suspected patients with PSP, potentially
                      facilitating more reliable diagnosis of PSP.},
      keywords     = {Aged / Biomarkers: metabolism / Cross-Sectional Studies /
                      Diagnosis / Female / Fluorine Radioisotopes:
                      pharmacokinetics / Gray Matter: diagnostic imaging / Gray
                      Matter: metabolism / Humans / Male / Middle Aged / Multiple
                      System Atrophy: diagnostic imaging / Multiple System
                      Atrophy: metabolism / Parkinson Disease: diagnostic imaging
                      / Parkinson Disease: metabolism / Positron-Emission
                      Tomography: standards / Pyridines: pharmacokinetics /
                      Sensitivity and Specificity / Severity of Illness Index /
                      Supranuclear Palsy, Progressive: diagnostic imaging /
                      Supranuclear Palsy, Progressive: metabolism / tau Proteins:
                      metabolism / ((18)F)PI-2620 (NLM Chemicals) / Biomarkers
                      (NLM Chemicals) / Fluorine Radioisotopes (NLM Chemicals) /
                      Pyridines (NLM Chemicals) / tau Proteins (NLM Chemicals)},
      cin          = {Clinical Dementia Research München / AG Jessen / AG Herms
                      / AG Höglinger 2 / AG Boecker},
      ddc          = {610},
      cid          = {I:(DE-2719)1111016 / I:(DE-2719)1011102 /
                      I:(DE-2719)1110001 / I:(DE-2719)1111015 /
                      I:(DE-2719)1011202},
      pnm          = {344 - Clinical and Health Care Research (POF3-344) / 342 -
                      Disease Mechanisms and Model Systems (POF3-342)},
      pid          = {G:(DE-HGF)POF3-344 / G:(DE-HGF)POF3-342},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33165511},
      pmc          = {pmc:PMC7341407},
      doi          = {10.1001/jamaneurol.2020.2526},
      url          = {https://pub.dzne.de/record/154698},
}